Treatment of heart failure with reduced ejection fraction has undergone an enormous development over the latest three decades resulting in lower mortality. Standard treatment now includes use of angiotensin-converting-enzyme (ACE)-inhibitors, beta blockers and mineralocorticoid receptor antagonists. Diuretics are still the cornerstone in the symptomatic treatment of fluid retention. Combined angiotensin II receptor blockade and neprilysin inhibition is a new treatment option instead of ACE-inhibition for selected patients. Cardiac resynchronisation therapy and prophylactic implantable cardiac defibrillators further reduce mortality.